Purpose: To describe ophthalmic manifestations in a series of patients with multiple myeloma (MM) and review the literature. Design: Retrospective case series. Methods: Review of all cases with ophthalmic manifestations of MM seen at the Department of Ophthalmology, Royal Adelaide Hospital, between 1987 and 2002. Results: Of all patients with MM who were managed at the Royal Adelaide Hospital in the study period, only 8 were referred to the Ophthalmology Department with ophthalmic manifestations. Five males and 3 females with a mean age of 61.25 years (range 42–78) who exhibited ophthalmic manifestations were studied. Six patients (75%) had known MM at the time of their ophthalmic evaluation. Four patients (50%) had neuro-ophthalmic symptoms resulting in diplopia or visual disturbances. Three patients (37.5%) presented with orbital involvement and 1 (12.5%) with hyperviscosity retinopathy. Five patients (62.5%) died within 2 months of their ophthalmic presentation. Conclusion: Ophthalmic manifestations of MM are uncommon and diverse. They may appear at the initial presentation of the disease or occur late in the disease process. Awareness of the possible manifestations may lead to an earlier diagnosis and have a positive influence on the disease course.

1.
Adkins JW, Shields JA, Shields CL, Eagle RC Jr, Flanagan JC, Campanella PC: Plasmacytoma of the eye and orbit. Int Ophthalmol 1996–7;20:339–343.
2.
Orellana J, Friedman AH: Ocular manifestations of multiple myeloma, Waldenström’s macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol 1981;26:157–169.
3.
Knapp AJ, Gartner S, Henkind P: Multiple myeloma and its ocular manifestations. Surv Ophthalmol 1987;31:343–351.
4.
Ashton N: Ocular changes in multiple myelomatosis. Arch Ophthalmol 1965;73:487–494.
5.
Lewis RA, Falls JF, Troyer DA: Ocular manifestations of hypercupremia associated with multiple myeloma. Arch Ophthalmol 1975;93:1050–1053.
6.
Aronson SA, Shaw R: Corneal crystals in multiple myeloma. Arch Ophthalmol 1959;61:541–546.
7.
Gudas PP: Optic nerve myeloma. Am J Ophthalmol 1971;71:1085–1089.
8.
Sanders TE, Podos SM, Rosenbaum LJ: Intraocular manifestations of multiple myeloma. Arch Ophthalmol 1967;77:789–794.
9.
Hawkins AS, Stein RM, Gaines BG, Deutsch TA: Ocular deposition of copper associated with multiple myeloma. Am J Ophthalmol 2001;131:257–259.
10.
Klintworth GK, Bredehoeft SJ, Reed JW: Analysis of corneal crystalline deposits in multiple myeloma. Am J Ophthalmol 1978;86:303–313.
11.
Pinkerton RMH, Robertson DM: Corneal and conjunctival changes in dysproteinemia. Invest Ophthalmol 1969;8:357–364.
12.
Allen RA, Miller DH, Straatsma BR: Cysts of posterior ciliary body (pars plana). Arch Ophthalmol 1961;66:302–313.
13.
Baker TR, Spencer WH: Ocular findings in multiple myeloma. Arch Ophthalmol 1974;91:110–113.
14.
Shami MJ, Uy RN: Isolated cotton-wool spots in a 67-year-old woman. Surv Ophthalmol 1996;40:413–415.
15.
Rootman J: Disease of the Orbit: A Multidisciplinary Approach. Philadelphia, Lippincott, 1988.
16.
Rodman HI, Font RL: Orbital involvement in multiple myeloma. Review of the literature and report of three cases. Arch Ophthalmol 1972;87:30–35.
17.
McFadzean RM: Orbital plasma cell myeloma. Br J Ophthalmol 1975;59:164–165.
18.
Ugurlu S, Bartley GB, Gibson LE: Necrobiotic xanthogranuloma: Long-term outcome of ocular and systemic involvement. Am J Ophthalmol 2000;129:651–657.
19.
Keung YK, Yung C, Wong JW, Shah F, Cobus E: Association of temporal arteritis, retinal vasculitis and xanthomatosis with multiple myeloma. Case report and literature review. Mayo Clin Proc 1998;73:657–660.
20.
Clark E: Plasma cell myeloma of the orbit. Br J Ophthalmol 1953;37:543–554.
21.
Jonasson F: Orbital plasma cell tumours. Ophthalmologica 1978;177:152–157.
22.
Henderson JW: Orbital Tumours. Philadelphia, Saunders, 1973, pp 400–404.
23.
Forrest AW: Intraorbital tumours. Arch Ophthalmol 1949;41:198–232.
24.
Benjamin I, Taylor H, Spindler J: Orbital findings in multiple myeloma. Arch Ophthalmol 1975;63:811–817.
25.
Levin SR, Spaulding AG, Wirman JA: Multiple myeloma. Orbital involvement in a youth. Arch Ophthalmol 1977;95:642–644.
26.
Danis P, Brauman S, Coppes P: Lesions of the fundus of the eye found in certain hyperproteinemias, particularly those of myelomatous origin. Acta Ophthalmol 1955;33:33–52.
27.
Delaney WV, Liarcos SV: Chorioretinal destruction in multiple myeloma. Am J Ophthalmol 1968;66:52–55.
28.
Carr RE, Henkind P: Retinal findings associated with serum hyperviscosity. Am J Ophthalmol 1963;56:23–31.
29.
Brown GC, Brown MM, Hiller T, et al: Cotton wool-spots. Retina 1985;5:206–214.
30.
Slansky HH, Bronstein M, Gartner S: Ciliary body cysts in multiple myeloma. Arch Ophthalmol 1966;76:686–689.
31.
Zweegman S, Huijgens PC: Treatment of myeloma. Recent developments. Anticancer Drugs 2002;13:339–351.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.